Cordlife GroupCLIFF 41 9-Day RSI is 100.00 as of Jul. 01, 2026. GuruFocus rates CLIFF with a GF Score™ of 41/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 66.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-01), Cordlife Group's 9-Day RSI is 100.00.
The industry rank for Cordlife Group's 9-Day RSI or its related term are showing as below:
CLIFF's 9-Day RSI is ranked worse than 66.06% of 218
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.19
vs CLIFF: 100.00
Cordlife Group (OTCPK:CLIFF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Cordlife Group 9-Day RSI Related Terms
CLIFF vs TMO, DHR, IDXX: 9-Day RSI Comparison
For the Diagnostics & Research subindustry, Cordlife Group's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group 9-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Cordlife Group's 9-Day RSI falls into.
Cordlife Group (OTCPK:CLIFF) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a 9-Day RSI of 100.00 as of Jul. 01, 2026. According to the industry distribution chart, Cordlife Group ranks #144 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 66.1%.
Is Cordlife Group's 9-Day RSI too high?
Cordlife Group's current 9-Day RSI is 100.00. The Medical Diagnostics & Research industry median 9-Day RSI is 50.19. Cordlife Group's value of 100.00 is 99.2% above this industry median. Based on the distribution chart, Cordlife Group ranks #144 out of 218 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cordlife Group has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's 9-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #144 out of 218 companies for 9-Day RSI. This places Cordlife Group in the lower half of its industry. The industry median 9-Day RSI is 50.19. Cordlife Group's value of 100.00 is 99.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Diagnostics & Research company?
The median 9-Day RSI among Medical Diagnostics & Research companies is 50.19, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current 9-Day RSI of 100.00 is 99.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median 9-Day RSI is 50.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current 9-Day RSI is 100.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current 9-Day RSI is 100.00 and 99.2% above the Medical Diagnostics & Research industry median of 50.19. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current 9-Day RSI is 100.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
9-Day RSI: 100.00
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 99.2% above the Medical Diagnostics & Research median (#144 of 218)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score
Get the complete analysis for CLIFF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 